TR200201954T2 - Viral hastalıklar için tıbbi maddeler. - Google Patents

Viral hastalıklar için tıbbi maddeler.

Info

Publication number
TR200201954T2
TR200201954T2 TR2002/01954T TR200201954T TR200201954T2 TR 200201954 T2 TR200201954 T2 TR 200201954T2 TR 2002/01954 T TR2002/01954 T TR 2002/01954T TR 200201954 T TR200201954 T TR 200201954T TR 200201954 T2 TR200201954 T2 TR 200201954T2
Authority
TR
Turkey
Prior art keywords
viral diseases
medicinal substances
substances
isoxalols
dihydropyrimidines
Prior art date
Application number
TR2002/01954T
Other languages
English (en)
Inventor
Brands Michael
Nicolic Susanne
Eckenberg Peter
Bauser Marcus
Kaulen Johannes
Paessens Arnold
Graef Erwin
Weber Olaf
Lottmann Stefan
Schlemmer Karl-Heinz
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000109408 external-priority patent/DE10009408A1/de
Priority claimed from DE2000132874 external-priority patent/DE10032874A1/de
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of TR200201954T2 publication Critical patent/TR200201954T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Izoksaloller yüksek ölçüde etkili anti-viral maddelerdir. Izoksazoller, dihidropirimidinler ve/veya lamivudinin kombinasyonlari ve istege göre interferon HBV virüslerinin çogalmasini geleneksel maddelere göre daha iyi engellemektedir.
TR2002/01954T 2000-02-28 2001-02-19 Viral hastalıklar için tıbbi maddeler. TR200201954T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2000109408 DE10009408A1 (de) 2000-02-28 2000-02-28 Arzneimittel gegen virale Erkrankungen
DE2000132874 DE10032874A1 (de) 2000-07-06 2000-07-06 Arzneimittelkombinationen gegen virale Erkrankungen

Publications (1)

Publication Number Publication Date
TR200201954T2 true TR200201954T2 (tr) 2002-12-23

Family

ID=26004561

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01954T TR200201954T2 (tr) 2000-02-28 2001-02-19 Viral hastalıklar için tıbbi maddeler.

Country Status (13)

Country Link
US (1) US20030187028A1 (tr)
EP (1) EP1286974A2 (tr)
JP (1) JP2003526639A (tr)
KR (1) KR20020079963A (tr)
CN (1) CN1406233A (tr)
AU (1) AU3739801A (tr)
BR (1) BR0108723A (tr)
CA (1) CA2401405A1 (tr)
IL (1) IL151188A0 (tr)
MX (1) MXPA02008418A (tr)
PL (1) PL365124A1 (tr)
TR (1) TR200201954T2 (tr)
WO (1) WO2001064755A2 (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
CA2633400A1 (en) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl urea for treating virus infections
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN104144924B (zh) * 2012-03-31 2016-02-24 弗·哈夫曼-拉罗切有限公司 用于治疗和预防乙型肝炎病毒感染的4-甲基-二氢嘧啶类
EP2953945A2 (en) * 2013-02-07 2015-12-16 Tobira Therapeutics, Inc. Lamivudine salts
CN109970675A (zh) * 2018-05-28 2019-07-05 中国医学科学院医药生物技术研究所 一组硫脲化合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2126329A (en) * 1936-03-20 1938-08-09 Hoffmann La Roche Amide derivatives of isoxazole carboxylic acids
ATE143262T1 (de) * 1992-12-29 1996-10-15 Abbott Lab Inhibitoren der retroviralen protease
DE69937904T2 (de) * 1998-03-11 2009-01-02 James W. Oak Park Williams Antivirale verwendungen von leflunomid produkten

Also Published As

Publication number Publication date
WO2001064755A3 (de) 2002-06-20
EP1286974A2 (de) 2003-03-05
CA2401405A1 (en) 2001-09-07
WO2001064755A2 (de) 2001-09-07
PL365124A1 (en) 2004-12-27
AU3739801A (en) 2001-09-12
JP2003526639A (ja) 2003-09-09
IL151188A0 (en) 2003-04-10
KR20020079963A (ko) 2002-10-21
US20030187028A1 (en) 2003-10-02
CN1406233A (zh) 2003-03-26
MXPA02008418A (es) 2003-02-12
BR0108723A (pt) 2002-12-03

Similar Documents

Publication Publication Date Title
DE50102597D1 (de) Arzneimittel gegen virale erkrankungen
DK1001801T3 (da) Produkt omfattende mindst en dobbeltkædet RNA kombineret med mindst et interferon til behandling af viral hepatitis
DK0821690T3 (da) Nukleotidanaloger til behandling af virusinfektioner
ID21649A (id) Inhibitor serum protease, terutama virus hepatitis c ns3 protease
FR20C1016I1 (tr)
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
DE122012000004I1 (de) Peptide als inhibitoren der NS3-Serinprotease des hepatitis c virus.
ATE318590T1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
NO991700D0 (no) Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
DK1169339T3 (da) Makrocykliske peptider, der inhiberer Hepatitis C-virus NS3-protease
UA85536C2 (en) Viral antigens
ATE555794T1 (de) Heilmittel gegen hepatitis
GB9825946D0 (en) Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
ATE384522T1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
TR200201954T2 (tr) Viral hastalıklar için tıbbi maddeler.
TR199501718A2 (tr) Papaya ringspot virüsü proteaz geni.
AU2001292125A1 (en) Genetic factors affecting the outcome of viral infections
EP1141255A4 (en) MODIFIED FORMS OF HEPATITIS C VIRUS NS3 PROTEASE
PT1220858E (pt) Oxazinoquinolonas uteis para o tratamento de infeccoes virais
TR199501557A2 (tr) PreS2 peptid iceren hepatiti b viral yüzey antijenini aritma prosesi.
EE200200693A (et) Interferoon hulgiskleroosi raviks
DK1173194T3 (da) Rekombinant SP-A til behandlingen eller forebyggelsen af lungeinfektion og -inflammation
ITRM20000327A0 (it) Proteina di fusione, particelle virali chimeriche che la espongono sul capside, piante infettate con tali particelle, loro usi e composizion
DK0952982T3 (da) Hidtil ukendte hepatitis B inhibitorer